Equities

Tempo Scan Pacific Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TSPC:JKT

Tempo Scan Pacific Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)2,760.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.77m
  • 1 Year change+15.97%
  • Beta0.5330
Data delayed at least 10 minutes, as of Feb 12 2026 09:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Tempo Scan Pacific Tbk is an Indonesia-based company engaged in the pharmaceuticals, consumer products, and cosmetics industry. The Company's segments include Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. The Pharmaceuticals segment conducts marketing of consumer health products, including over-the-counter drugs, vitamins, minerals and supplements (VMS), beverages, nutritional products, herbal products, and prescription medicines. The Consumer Products and Cosmetics segment markets and distributes its own branded products as well as licensed cosmetics products. The Distribution Services segment distributes products to customers and serves customers from various sales branches throughout Indonesia, covering pharma, modern trade, and general trade channels. It also markets and distributes its products overseas through its international business units. Its business network covers approximately 238 locations consisting of over 48 branches.

  • Revenue in IDR (TTM)13.64tn
  • Net income in IDR1.50tn
  • Incorporated1971
  • Employees4.40k
  • Location
    Tempo Scan Pacific Tbk PTLantai 16, Tempo Scan TowerJl. HR. Rasuna Said Kav. 3-4JAKARTA 12950IndonesiaIDN
  • Phone+62 2 129218888
  • Fax+62 2 129209999
  • Websitehttps://www.temposcangroup.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pharmanutra SpA2.52tn347.56bn12.11tn136.0034.559.1130.404.801.821.8213.146.891.080.44114.921,101,148.0014.7217.2619.6622.9096.8396.0613.6817.091.86680.620.241153.7115.2716.5929.4314.46-2.6516.80
Ironwood Pharmaceuticals, Inc.5.69tn479.05bn12.12tn253.0031.62--23.722.130.14040.14042.00-1.620.863--3.451,339,870.007.27-6.0811.57-7.13----8.42-11.01--4.731.82---20.63-3.89100.09-56.87-54.38--
Ocumension Therapeutics1.32tn-605.22bn12.13tn505.00--1.36--9.19-0.3764-0.37640.82145.080.15714.303.351,257,846.00-7.20-24.03-7.62-25.7142.5858.38-45.84-400.904.86--0.0223--69.38365.9529.36--213.01--
Tong Ren Tang Technologies Co Ltd16.87tn1.05tn12.21tn3.89k11.640.6894.600.72350.38130.38136.146.440.4820.86156.001,969,449.005.477.448.5712.0739.8242.2111.3415.102.79--0.191339.347.1810.15-11.594.55-8.303.37
Zeria Pharmaceutical Co Ltd9.48tn795.26bn12.34tn1.75k13.381.017.751.30164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Tempo Scan Pacific Tbk PT13.64tn1.50tn12.45tn4.40k8.291.336.330.9127332.96332.963,025.002,081.511.073.759.033,044,214,000.0012.1410.7116.3714.6637.6035.8711.319.062.51--0.094443.454.084.4322.9621.173.6420.11
Shanghai New World Co Ltd2.68tn167.67bn12.53tn1.14k74.811.22--4.670.10670.10671.716.570.19623.9311.76968,234.301.220.63941.610.883840.3936.386.203.581.56--0.111871.59-1.21-7.49121.2213.84-26.505.92
Aarti Pharmalabs Ltd3.52tn443.38bn12.57tn2.16k28.353.3220.403.5726.4526.45210.27225.750.63091.394.228,812,209.007.94--10.54--51.04--12.58--0.87069.620.2435--14.17--25.59------
Jianmin Pharmaceutical Group Co Ltd7.71tn792.00bn12.66tn2.35k15.762.02--1.642.162.1621.0116.830.74353.943.461,354,202.007.7710.9612.8319.5860.5244.4110.4510.231.40--0.043837.54-16.819.38-30.5431.6811.6635.10
Data as of Feb 12 2026. Currency figures normalised to Tempo Scan Pacific Tbk PT's reporting currency: Indonesian Rupiah IDR

Institutional shareholders

0.63%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 08 Jan 202611.17m0.25%
FIL Investment Management (Singapore) Ltd.as of 31 Dec 20256.66m0.15%
Grantham, Mayo, Van Otterloo & Co. LLCas of 30 Nov 20254.56m0.10%
Jennison Associates LLCas of 30 Sep 20253.12m0.07%
Dimensional Fund Advisors Ltd.as of 30 Nov 2025755.81k0.02%
FIL Investments Internationalas of 30 Jun 2025607.80k0.01%
Monega Kapitalanlagegesellschaft mbHas of 30 Dec 2025600.00k0.01%
American Century Investment Management, Inc.as of 08 Jan 2026386.00k0.01%
State Board of Administration of Florida Retirement Systemas of 30 Sep 2025237.61k0.01%
PT Indo Premier Securities (Investment Management)as of 28 May 2025235.77k0.01%
More ▼
Data from 28 May 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.